Taming the escalating costs of Ireland’s community drugs schemes

Authors

  • Duncan Fortescue-Webb School of Medicine, Trinity College, University of Dublin, Ireland

Keywords:

Medicine

Abstract

A reduced public budget has increased pressure to improve the efficiency of healthcare provision in Ireland. Legislative changes to reduce margins throughout the drugs supply chain and increase patient co-payments have recently been implemented. The background and implications of these changes are considered for manufacturers, wholesalers, pharmacists, patients and the public purse. Together, the changes are predicted to reduce the cost of providing drugs in the community in 2010 by nearly €270 million (11% of the projected €2.4 billion they would otherwise cost). However, underlying growth trends in drugs expenditure, particularly in the burgeoning high-tech drugs market, mean that although recent changes should contain the cost of drugs in 2010 at a level similar to 2009, annual growth of 12% is likely to resume thereafter unless additional reform is implemented. Slated future legislative changes that could be worth a further €200 million or more annually include: reference pricing, pharmacist-led substitution, renegotiation of manufacturer prices, and disinvestment of non-cost-effective drugs from public schemes. Finally, ways to improve prescriber habits are considered that could save an additional €100 million annually. These include periodic and critical reviews of patient prescriptions, more judicious use of antibiotics, generic prescribing, prescriber awareness of drug prices, and provision of prescribing software.

References

1. Health Estimates for 2010. Department of Health and Children. 9 December 2009. Available from: www.dohc.ie/press/releases/2009/20091209.html
2. Annual Report and Financial Statements 2008. Health services Executive. May 2009. Available from: www.hse.ie/eng/services/Publications/corporate/ arafs08.pdf
3. Statistical analysis of claims and payments 2008. Primary Care Reimbursement Service. Available from: www.hse.ie/eng/staff/PCRS/PCRS_Publications/ FSA2008.pdf
4. Barry M, Boland R, Bradley C, Devlin J, Hughes C, Logan P, et al. Economies in Drug Usage in the Irish Healthcare Setting. 2009. Available from: www. dohc.ie/publications/pdf/economies_drug_usage. pdf?direct=1
5. Pharmaceuticals: Europe Industry Guide. Datamonitor. April 2009. Available from: www. bioportfolio.com/cgi-bin/acatalog/Pharmaceuticals- Europe-Industry-Guide.html
6. Why Ireland should be your location of choice. Pharmachemical Ireland. 2009. Available from: www.pharmachemicalireland.ie/Sectors/PCI/PCI. nsf/vPages/News_and_events~ireland-as-a-location- of-choice-03-12-2009/$file/Ireland%20as%20a%20 location%20of%20choice.pdf
7. Research and Development. Irish Pharmaceutical Healthcare Association. Available from: www.ipha. ie/alist/medicines-innovation.aspx
8. Coughlan JJ, Fortescue-Webb D, Heaney R, Judge G, Tilson L, Barry M. ISPOR Global Health Care Systems Road Map. June 2009. Available from: www.ispor.org/HTARoadMaps/Ireland.asp
9. Barry M, Molloy D, Usher C, Tilson L. Drug expenditure in Ireland 1997 – 2007. IMJ November 2008. IMJ 101(10):299-302. Available from: www.imj. ie/Issue_detail.aspx?issueid=+&pid=3860&type=Pa pers
10. Barry M, Tilson L. Recent developments in pricing and reimbursement of medicines in Ireland. Expert Rev. Pharmacoeconomics Outcomes Res. 2007 7(6), 605 – 611 Available from: www.expert-reviews.com/ doi/abs/10.1586/14737167.7.6.605
11. Pricing and Reimbursement of Medicines – February 2010. Department of Health and Children. February 2010. Available from: www.dohc.ie/fact_ sheets/pr_medicines_201002.pdf?direct=1
12. Your Guide to the Long-Term Illness Scheme. Health Service Executive. 21 October 2009. Available from: www.hse.ie/eng/services/Find_a_Service/ entitlements/Long_Term_Illness
13. 2006 IPHA/HSE Agreement. Available from: www. ipha.ie/GetAttachment.aspx?id=76a31074-9c28-4917- af35-b3546572a415
14. Harney M. Written Answers, 11 February
2010. Available from: www.kildarestreet.com/ wrans/?id=2010-02-11.614.0
15. Wall M. Switch to generic drugs saves
€15m, not €200m. Irish Times. 14 April 2009. Available from: www.irishtimes.com/newspaper/ health/2009/0414/1224244622790.html
16. A fair price for wholesalers means lower medicine prices. Health Service Executive. 25 February
2008. Available from: www.hse.ie/eng/services/ news/2008_Archive/Feb_2008/A_Fair_Price_for_ Wholesale_Services_Means_Lower_Medicine_Prices. html
17. Minister Harney announces reductions in payments to community pharmacists to reduce rapid rise in State expenditure on drugs and medicines. Department of Health and Children. 18 June 2009. Available from: www.dohc.ie/press/ releases/2009/20090618.html
18. Health Professionals (Reduction of Payments
to Community Pharmacy Contractors) Regulations 2009. Department of health and Children. 1 July 2009. Available from: www.dohc.ie/legislation/ statutory_instruments/pdf/si20090246.pdf?direct=1 19. Generic drug utilisation in Ireland 2008. National Centre for Pharmacoeconomics. April 2009. Available from: www.ncpe.ie/u_docs/doc_163.pdf 20. Donnellan E. Prescription for big savings.
Irish Times. 2 February 2010. Available
from: www.irishtimes.com/newspaper/ health/2010/0202/1224263572987.html
21. Data taken from the Retail Pharmacy Business Register of The Pharmaceutical Society of
Ireland. February 16 2010. Available from: public. pharmaceuticalsociety.ie
22. Statistical Analysis of Claims and Payments 2005. Primary Reimbursement Service. Available from: www.hse.ie/eng/Staff/PCRS/PCRS_Publications/ Primary_Care_Reimbursement_Service_Financial_ and_Statistical_Analysis_2005.pdf
23. Noonan L. Pharmacy ownership scheme collapses. Irish Independent. 5 February 2010. Available from: www.independent.ie/business/irish/ pharmacy-ownership-scheme-collapses-2049465. html
24. Goldman DP, Joyce GF, Yuhui Zeng. Prescription Drug Cost Sharing: Associations with Medication and Medical Utilization and Spending and Health, JAMA 2007;298:61-69. Available from: jama.ama-assn.org/ cgi/content/full/298/1/61
25. Culliton G. Pricing ourselves out of the market? Irish Medical Times. 31 July 2009. Available from: www.imt.ie/opinion/2009/07/pricing_ourselves_out_ of_the_m.html
26. Aaserud M, Austvoll-Dahlgren A, Kösters JP,
Oxman AD, Ramsay C, Sturm H. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database
of Systematic Reviews 2006, Issue 2. Art. No.: CD005979. Available from: www.cochrane.org/ reviews/en/ab005979.html
27. Generic Prescribing. National Medicines Information Centre. Volume 15 Number
1. 2009. Available from: www.stjames.ie/ GPsHealthcareProfessionals/Newsletters/ NMICBulletins/Generic%20bulletin%20NMIC%20 v15No1%20web%20with%20refs.pdf
28. Konijn P. Pharmaceutical products – comparative price levels in 33 European countries in 2005. Statistics in Focus, Economy and Finance. 45/2007.
2 February 2007. Available from: epp.eurostat. ec.europa.eu/cache/ITY_OFFPUB/KS-SF-07-045/EN/ KS-SF-07-045-EN.PDF
29. The role of oral nutritional supplements in primary care. National Medicines Information Centre. 2004; 10;2. Available from: www.stjames. ie/GPsHealthcareProfessionals/Newsletters/ NMICBulletins/NMICBulletins2004/The%20Role%20 of%20Oral%20Nutritional%20Supplements%20in%20 Primary%20Care%20Vol.10%20No.2%202004.pdf
30. Drugs worth €46 million inappropriately prescribed to elderly. Centre for Ageing Research and Development in Ireland. 18 September 2009. Available from: www.cardi.ie/?q=news/drugsworth %E2%82%AC46millioninappropriatelyprescribedtoe lderly
31. Policy Group on Healthcare-Associated
Infection. Antibiotic Use And The Implications For Healthcare-Associated Infection. Royal College
of Physicians of Ireland. 22 September 2009. Available from: www.rcpi.ie/News/Documents/ AntibioticUseandImplicationsforHCAI.pdf
32. Mitchell S. HSE’s Bitter Pill to Swallow. Sunday Business Post. 22 November 2009. Available from: archives.tcm.ie/businesspost/2009/11/22/story45786. asp
33. Cunney R. Antibiotic Use and Antibiotic Resistance in Ireland. HSPC. November 2008. Available from: www.hpsc.ie/hpsc/A-ZMicro biologyAntimicrobialResistanceEuropeanSu rveillanceofAntimicrobialConsumptionESAC/ EuropeanAntibioticAwarenessDay/File,3240,en.pdf 34. McGowan B, Bergin C, Bennett K, Barry M. Utilisation of Antibiotic Therapy in Community Practice. Ir Med J October 2008 273-6. Available from: www.imj.ie/UserControls/WritePDF/ISSUE342/ Original_Paper_Utilisation_of_Antibiotic.pdf
35. Prescriptions Dispensed in the Community Statistics for 1998 to 2008: England. The NHS Information Centre, Prescribing Support Unit. 29 July 2009. Available from: http://www.ic.nhs.uk/ webfiles/publications/presdisp98-08/Prescriptions_ Dispensed_in_the_Community_1998_2008_ England_a.pdf
36. Gisbert JP, Pajares JM. Esomeprazole-based therapy in Helicobacter pylori eradication: a meta- analysis. Digestive and Liver Disease. April 2004 Volume 36, Issue 4, pp. 253-259. Available from: www.ncbi.nlm.nih.gov/pubmed/15115337
37. Harris G. 2 New Fronts in Heartburn Market Battle. New York Times. 20 August 2003.
Available from: www.nytimes.com/2003/08/20/ business/2-new-fronts-in-heartburn-market-battle. html?pagewanted=1

Downloads

Published

2010-01-01

How to Cite

Fortescue-Webb, D. (2010). Taming the escalating costs of Ireland’s community drugs schemes. Trinity Student Medical Journal , 11(1), Page 6–12. Retrieved from https://ojs.tchpc.tcd.ie/index.php/tsmj/article/view/1831

Similar Articles

<< < 2 3 4 5 6 7 8 9 10 11 > >> 

You may also start an advanced similarity search for this article.